



Important Dates

June 4-8, 2021 ASCO Annual Meeting Virtual Scientific Program

June 4, 2021 On-demand content available

ASCO News

Everett E. Vokes, MD – Elected ASCO president for 2021-2022 term

Read more in the following links:

- <https://ascopost.com/issues/june-3-2020-narratives-special-issue/from-the-united-states-to-germany-and-back-again-to-become-asco-president-in-2021-2022/>
- <https://www.asco.org/about-asco/press-center/news-releases/everett-e-vokes-md-fasco-elected-asco-president-2021-2022-term>
- <http://medicine.uchicago.edu/everett-e-vokesmd-elected-asco-president/>

Sonali Smith, MD – Recipient of 2021 ASCO Excellence in Teaching Award

- <https://www.asco.org/about-asco/press-center/news-releases/asco-honors-2021-special-awards-recipients>

Amy Wang, MD, MPH – Recipient of 2021 ASCO Brigid Leventhal Special Merit Award

- <https://www.conquer.org/news/conquer-cancer-announces-2021-asco-annual-meeting-merit-award-recipients>

All times CDT

Events

Opening Session with Presidential Address

June 5, 2021 7:30-9:00am

Plenary Session

June 6, 2021 12:00-3:00pm

Discussion: Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial

Discussant: **Kunle Odunsi**

Panel Question and Answer with Drs. Pierce, Henry, Mileschkin, and **Odunsi**

#ASCO21

Education Sessions

June 4, 2021 8:00am

Understanding the science driving immunotherapies in melanoma

Speaker: **Thomas Gajewski**

June 4, 2021 8:00am

The oncology workforce 2021: Evidence on the impact of burnout, moral strain, and COVID-19 on oncology clinician well-being

Chair: **Fay Hlubocky**

June 4, 2021 8:00am

Financially guided dosing

Speaker: **Mark Ratain**

June 7, 2021 10:30am

Clinical implications of HER-2/Neu in GI cancers and beyond

Speaker: **Daniel Catenacci**

Highlights of the Day Session

June 4, 2021 5:00pm

Highlights of Lung Cancer – Non-Small Cell Metastatic

Discussant: **Marina Garassino**

Clinical Science Symposium

June 4, 2021 8:00am

FIGHT: A randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2+ advanced gastric/gastroesophageal junction adenocarcinoma (GC).

Authors: **Daniel Catenacci**...Zev Wainberg.

June 4, 2021 8:00am

Outcomes in patients (pts) aged ≥ 65 years in the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC).

Authors: Kevin Kalinsky...**Rita Nanda**...Sibylle Loibl.

Case-Based Panel

June 8, 2021 10:30am

Perspective on Immunotherapy and other novel molecular targets in head and neck squamous cell carcinoma

Speaker: **Alexander Pearson**

Oral Abstract Sessions

#ASCO21

June 4, 2021 1:30pm

Pharmacogenomics of cisplatin-induced neurotoxicities: Hearing loss, tinnitus and peripheral sensory neuropathy.

Authors: Xindi Zhang...**Eileen Dolan**...Lois Travis.

June 4, 2021 1:30pm

Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).

Authors: Bijal Shah...**Michael Bishop**...Roch Houot.

June 5, 2021 9:00am

Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study.

Authors: Alanna Church...**Mark Applebaum**...Katherine Janeway.

June 5, 2021 12:30pm

Breast Cancer-Metastatic Session

Chair: **Olwen Hahn**

June 5, 2021 12:30pm

Breast Cancer-Metastatic Session

Chair: **Olwen Hahn**

June 6, 2021 7:00am

Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial.

Authors: Amy Chien...**Rita Nanda**...Laura Esserman.

June 6, 2021 7:00am

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).

Authors: Jonathan Spicer...**Everett Vokes**...Stephen Broderick.

June 6, 2021 7:00am

Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538.

Authors: Jeffrey Bogart...**Everett Vokes**.

June 7, 2021 7:00am

CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.

Authors: Nizar Tannir...**Walter Stadler**...Bernard Escudier.

June 7, 2021 7:00am

#ASCO21

Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.

Authors: Arjun Balar...**Peter O'Donnell**...William Huang.

June 7, 2021 7:00am

First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.

Authors: **Peter O'Donnell**...Ronald De Wit.

June 7, 2021 10:30am

Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial.

Authors: Stephen Schuster...**Peter Riedell**...Catherine Thieblemont.

June 7, 2021 10:30am

Fine-Tuning Intensity in Lymphoma Treatment

Discussant: **Sonali Smith**

Panel Discussion with Drs. Popplewell, Lechowicz, Batchelor, LaCasce, Schuster, and **Smith**

June 7, 2021 2:00pm

First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers.

Authors: Alan Ho...**Alexander Pearson**...**Ari Rosenberg**...David Pfister.

June 7, 2021 2:00pm

COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716).

Authors: Daniel Vaena...**Gini Fleming**...Drew Rasco.

June 8, 2021 7:00am

Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.

Authors: Saad Zafar...**Andrzej Jakubowiak**...Sundar Jagannath.

June 8, 2021 7:00am

Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).

Authors: Nizar Bahlis...**Andrzej Jakubowiak**...Alexander Lesokhin.

Poster Discussion Sessions

All are available: *June 4, 2021* 8:00am

#ASCO21

Survival and organ preservation according to clinical response after total neoadjuvant therapy in locally advanced rectal cancer patients: A secondary analysis from the organ preservation in rectal adenocarcinoma (OPRA) trial

Authors: Hannah Thompson...**Blase Polite**...Julio Garcia-Aguilar.

Hearing loss after cisplatin-based chemotherapy: Patient-reported outcomes versus audiometric assessments.

Authors: Shirin Ardeshirrouhanifard...**Eileen Dolan**...Lois Travis.

Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial.

Authors: **Ari Rosenberg**, **Nishant Agrawal**, **Alexander Pearson**...**Elizabeth Blair**...**Evgeny Izumchenko**...**Everett Vokes**.

Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms

Authors: Vinod Pullarkat...**Michael Thirman**...Marina Potluri.

Follow-up of patients with *FLT3*-mutated R/R AML in the phase 3 ADMIRAL trial.

Authors: Alexander Perl, **Richard Larson**...Mark Levis.

Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.

Authors: Keith Pratz...**Michael Thirman**...Hartmut Dohner.

Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM).

Authors: **Benjamin Derman**...**Andrzej Jakubowiak**.

Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma

Authors: Matthew Frigault...**Michael Bishop**...Marcela Maus.

AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).

Helen Ross...**Everett Vokes**, Tom Stinchcombe.

Approaches to Achieving and Consolidating Remission in Neuroblastoma and Sarcoma

Discussant: **Ami Vijay Desai**

Financial hardship in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).

Authors: Paul Nathan...**Tara Henderson**...Robin Yabroff.

Efficacy of clinical breast examination in chest-irradiated female survivors of childhood Hodgkin lymphoma (HL).

Authors: Florence Wong...**Tara Henderson**...Smita Bhatia.

Neurocognitive outcomes in survivors of early adolescent and young adult (eAYA) hematologic cancers from the Childhood Cancer Survivor Study (CCSS)

Authors: Amy Wang...**Wendy Stock**...**Tara Henderson**.

#ASCO21

Abstracts and Posters

All are available: *June 4, 2021* 8:00am

Comparison of dose modification strategies to address expected hematologic toxicities in treatment-naïve higher-risk (HR) MDS patients treated with venetoclax + azacitidine.

Authors: Jacqueline Garcia...**Olatoyosi Odenike**...Guillermo Garcia-Manero.

Racial and ethnic disparities in risk and survival in children with neuroblastoma: An updated analysis.

Authors: Caileigh Pudela, **Mark Applebaum**...**Samuel Volchenboun**, **Tara Henderson**, **Susan Cohn**, **Ami Desai**.

Predicting response to chemotherapy in neuroblastoma using deep learning: A report from the International Neuroblastoma Risk Group.

Authors: Siddhi Ramesh...**Susan Cohn**, **Samuel Volchenboun**...**Mark Applebaum**.

Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study.

Authors: Alanna Church...**Mark Applebaum**...**Samuel Volchenboun**...Katherine Janeway.

Late morbidity and mortality among survivors of neuroblastoma treated with contemporary therapy: A report from the Childhood Cancer Survivor Study.

Authors: Danielle Friedman...**Susan Cohn**...**Tara Henderson**.

5-Hydroxymethylcytosines in circulating cell-free DNA and overall survival in patients with multiple myeloma

Authors: **Brian Chiu**...**Benjamin Derman**...**Andrzej Jakubowiak**, **Chuan He**, Wei Zhang.

Validation of the RSclin risk calculator using the National Cancer Database (NCDB).

Authors: Frederick Howard, **Alexander Pearson**, **Rita Nanda**, **Olufunmilayo Olopade**, **Dezheng Huo**.

Independent validation of simbiosys tumorscope to predict response to neoadjuvant chemotherapy (NACT) in early breast cancer (EBC).

Authors: Gong He, Frederick Howard...**Hiroyuki Abe**, **Rita Nanda**.

The clinician educator career in oncology

Authors: Meredith Giuliani...**Jennifer Tseng**...Jamie Von Roenn.

Effect of time to relapse on overall survival (OS) in Mantle cell lymphoma (MCL) patients (pts) following frontline high-dose therapy and autologous hematopoietic cell transplantation (autoHCT).

Authors: **Peter Riedell**...**Sonali Smith**.

Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.

Authors: Ulrich Jäger...**Peter Riedell**...Edmund Waller.

A phase II study of PRV111 nanoengineered cisplatin patch as a neoadjuvant therapy for early-stage oral squamous cell carcinoma (OSCC).

Authors: **Nishant Agrawal**, **Evgeny Izumchenko**...Manijeh Goldberg.

#ASCO21

Ultra-sensitive detection and quantification of HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OPTIMA 2 treatment de-escalation trial.

Authors: Hillary Sloane, **Evgeny Izumchenko**...**Alexander Pearson**, **Everett Vokes**...**Ari Rosenberg**, **Nishant Agrawal**.

Mathematical predication models to optimize post-treatment surveillance in HPV-associated oropharyngeal cancer.

Authors: Vivek Nair...**Evgeny Izumchenko**, **Nishant Agrawal**, **Ari Rosenberg**, **Everett Vokes**...**Alexander Pearson**.

Integration and feasibility of symptom burden assessment and early palliative care into an adolescent and young adult leukemia clinic.

Authors: Amy Wang...**Fay Hlubocky**, **Jennifer McNeer**, **Tara Henderson**, **Wendy Stock**, **Christopher Daugherty**.

A phase 4 study to evaluate outpatient blinatumomab in patients with minimal/measurable residual disease (MRD) positivity (+) of B-cell precursor acute lymphoblastic leukemia (BCP-ALL).

Authors: Sharif Khan...**Wendy Stock**...Timothy Pardee.

Low incidence of hepatic veno-occlusive disease (VOD) in patients with B-cell acute lymphoblastic leukemia (B-ALL) treated with inotuzumab ozogamicin (INO) followed by allogeneic stem cell transplantation (allo-SCT).

Authors: Kirk Cahill...**Hongtao Liu**, **Michael Bishop**, **Richard Larson**, **Wendy Stock**.

Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202.

Authors: Ghassan Abou-Alfa...**Daniel Catenacci**...Arndt Vogel.

Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (*IDH1*) mutation.

Authors: Ghassan Abou-Alfa...**Daniel Catenacci**...Andrew Zhu.

Phase 2 study of zolbetuximab plus mFOLFOX6 in claudin 18.2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma (G/GEJ): ILLUSTRO cohort 2.

Authors: Samuel Klemper...**Daniel Catenacci**...Yung-Jue Bang.

Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044

Authors: Neelima Vidula, **Rita Nanda**...Hope Rugo.

Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1+ hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC).

Authors: Ana Garrido-Castro...**Rita Nanda**...Sara Tolaney.

Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1- metastatic triple-negative breast cancer (mTNBC)

Authors: Ana Garrido-Castro...**Rita Nanda**...Dara Tolaney.

Patient out-of-pocket savings with lower-dose trastuzumab.

Authors: Marie Dreyer...**Rita Nanda**...**Mark Ratain**.

#ASCO21

Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hürthle cell thyroid cancer (HCC) (Alliance A091302/ ITOG 1706).

Authors: Eric Sherman...**Ardaman Shergill**...Gary Schwartz.

Supportive care services (SCS) during curative-intent treatment with chemoradiation for patients with locally advanced head and neck cancer (HNC).

Authors: Ethan Harris...**Ardaman Shergill**.

Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts.

Authors: Selina Wong...**Christine Bestvina**...Katy Beckermann.

Intracranial activity of tepotinib in patients (pts) with *MET* exon 14 (*MET*ex14) skipping NSCLC enrolled in VISION

Authors: Jyoti Patel...**Christine Bestvina**...**Marina Garassino**...Paul Paik.

Phase II two-arm study of tepotinib plus osimertinib in patients with *EGFR*-mutant NSCLC and acquired resistance to first-line osimertinib due to *MET* amplification: INSIGHT 2.

Authors: Viola Zhu, **Christine Bestvina**...Yi-Long Wu.

A phase I trial evaluating NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers.

Authors: Colette Shen...**Ari Rosenberg**...Tanguy Seiwert.

CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma

Authors: Deborah Wong...**Ari Rosenberg**...Ezra Cohen.

A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer.

Authors: Alberto Bessudo...**Ari Rosenberg**...Bertrand Liang.

Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050)

Authors: Erica Stringer-Reasor...**Rita Nanda**...Eddy Yang.

Trial in progress: A phase I/II trial of novel MDM2 inhibitor alrizomadlin (APG-115), with or without platinum chemotherapy, in patients with p53 wild-type salivary gland carcinoma.

Authors: Paul Swiecicki...**Alexander Pearson**...Yifan Zhai.